tirzepatide in westlake Results — Weight Loss Timeline & What to Expect Zepbound® Tirzepatide Weight Loss Program

AstraZeneca Advances #Oral #GLP-1 #Elecoglipron to #Phase #3 After Hitting Phase 2 Endpoints AstraZeneca confirmed that its oral GLP-1 candidate elecoglipron met primary endpoints in two Phase 2 trials and will now advance into Phase 3 while holding back detailed weight-loss data until June

L., Apperloo, E., Davies, M

Obesity is widely recognized as a primary risk factor for chronic diseases, largely because it triggers early biological aging at the cellular level

Furthermore, they may stimulate thyroid activity so caution is required in hyperthyroidism

Risk appears greater with higher GLP-1 doses and longer treatment duration, and may be more pronounced in those using these medications for weight management rather than diabetes alone, as shown in the 2022 JAMA Internal Medicine meta-analysis